The Business Research Company The Business Research Company's Beyfortus Global Market Report 2025 – Market Size, Trends, And Global Forecas ...

Estimated effectiveness was 65% against hospitalization, 74% against pediatric intensive care unit admission, and 64% against ...

It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...

Sanofi’s plan to become a dominant player in the respiratory syncytial virus (RSV) market has moved a step closer, with FDA approval of Beyfortus for the prevention of RSV disease in infants.

Yun Ki-wook, a professor in SNUH's Department of Pediatric Infectious Diseases, discusses the domestic release of Beyfortus, an antibody treatment for respiratory syncytial virus, during a press ...

A study today in JAMA Network Open from the University of California, San Francisco (UCSF), shows a high uptake of respiratory syncytial virus (RSV) vaccine and the RSV-preventing monoclonal antibody ...

The beyfortus market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX ...

Immunology saw significant contributions from Beyfortus royalties, although Synagis declined year-over-year. Pipeline progress included the U.S. filing for Gamifant in secondary HLH and the ...

Sanofi could be "bit more" active with M&A in near future, CFO says Sanofi's R&D spending to see limited increase in 2025 Beyfortus sales double, Dupixent sales miss estimates Jan 30 - Sanofi ...

Innovation was a key driver of our growth as launches already contributed 11 percent of sales, with Beyfortus becoming a blockbuster in its first full year of sales. We exceeded our business EPS ...

Management expects Beyfortus penetration to grow further with geographic expansion. Gross margin and R&D expenses are also anticipated to increase slightly in 2025, supported by preparations for u ...